Chemed Corporation reported service revenues and sales of $2,431.3 million for the full year 2024, reflecting a 7.4% increase from $2,264.4 million in 2023. Adjusted EBITDA rose by 11.3% to $503.0 million in 2024 from $451.9 million the previous year, with the adjusted EBITDA margin increasing by 0.7 percentage points to 20.7%. Adjusted net income grew by 13.8% to $351.2 million in 2024, compared to $308.5 million in 2023. Adjusted diluted earnings per share $(EPS)$ increased by 13.9% to $23.13 in 2024, up from $20.30 in 2023. Capital expenditures for 2024 were $49.5 million, a decrease of 12.9% from $56.9 million in 2023. For the nine months ended September 30, 2025, service revenues and sales were $1,890.6 million, up 5.5% from $1,791.3 million for the same period in 2024. Adjusted EBITDA for the period decreased by 8.8% to $326.1 million, and the adjusted EBITDA margin declined by 2.8 percentage points to 17.2%. Adjusted net income was $221.7 million, down 10.9% from $248.7 million. Adjusted diluted EPS declined by 7.1% to $15.16 from $16.31. Capital expenditures increased by 26.3% to $46.4 million from $36.8 million in the previous period. Chemed has reported a 21.3% compound annual growth rate in adjusted diluted EPS since 2003 and has engaged in share repurchases and dividend payments over the years, returning capital to shareholders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemed Corporation published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.
Comments